BR112017012287A2 - pan-fgfr inhibitors and method of identifying cancer patients eligible for treatment with a pan-fgfr inhibitor - Google Patents

pan-fgfr inhibitors and method of identifying cancer patients eligible for treatment with a pan-fgfr inhibitor

Info

Publication number
BR112017012287A2
BR112017012287A2 BR112017012287A BR112017012287A BR112017012287A2 BR 112017012287 A2 BR112017012287 A2 BR 112017012287A2 BR 112017012287 A BR112017012287 A BR 112017012287A BR 112017012287 A BR112017012287 A BR 112017012287A BR 112017012287 A2 BR112017012287 A2 BR 112017012287A2
Authority
BR
Brazil
Prior art keywords
pan
fgfr
treatment
cancer patients
patients eligible
Prior art date
Application number
BR112017012287A
Other languages
Portuguese (pt)
Inventor
Heroult Melanie
Ellinghaus Peter
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of BR112017012287A2 publication Critical patent/BR112017012287A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

uso de inibidores pan-fgfr e método de identificação de pacientes com câncer elegíveis para tratamento com um inibidor pan-fgfr. a invenção atual se baseia em um inibidor pan-fgfr para uso no tratamento de câncer em um paciente, em que o paciente é aquele para o qual a soma de mrna de fgfr1, fgfr2 e/ou fgfr3 em uma amostra de tecido tumoral está expressa em excesso.use of pan-fgfr inhibitors and method of identifying cancer patients eligible for treatment with a pan-fgfr inhibitor. The present invention is based on a pan-fgfr inhibitor for use in treating cancer in a patient, wherein the patient is one for which the sum of fgfr1, fgfr2 and / or fgfr3 mrna in a tumor tissue sample is expressed. too much.

BR112017012287A 2014-12-11 2015-12-08 pan-fgfr inhibitors and method of identifying cancer patients eligible for treatment with a pan-fgfr inhibitor BR112017012287A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14197400 2014-12-11
PCT/EP2015/078919 WO2016091849A2 (en) 2014-12-11 2015-12-08 Use of pan fgfr inhibitors and method of identifying patients with cancer eligible for treatment with a pan fgfr inhibitor

Publications (1)

Publication Number Publication Date
BR112017012287A2 true BR112017012287A2 (en) 2018-08-28

Family

ID=52015993

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017012287A BR112017012287A2 (en) 2014-12-11 2015-12-08 pan-fgfr inhibitors and method of identifying cancer patients eligible for treatment with a pan-fgfr inhibitor

Country Status (18)

Country Link
US (1) US20180333418A1 (en)
EP (1) EP3229800A2 (en)
JP (1) JP2017538708A (en)
KR (1) KR20170090431A (en)
CN (1) CN106999592A (en)
AU (1) AU2015359538A1 (en)
BR (1) BR112017012287A2 (en)
CA (1) CA2970181A1 (en)
CL (1) CL2017001487A1 (en)
EA (1) EA201791236A1 (en)
IL (1) IL252187B (en)
JO (1) JO3730B1 (en)
MX (1) MX2017007656A (en)
PH (1) PH12017501064A1 (en)
SG (1) SG11201704090WA (en)
SV (1) SV2017005459A (en)
TW (1) TW201628655A (en)
WO (1) WO2016091849A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6831135B2 (en) 2017-01-06 2021-02-17 レモネックス インコーポレイテッドＬｅｍｏｎｅｘ Ｉｎｃ． Compositions for the prevention or treatment of metastatic ovarian cancer, endometrial cancer or breast cancer
CN111247150B (en) * 2017-08-15 2022-11-08 石药集团中奇制药技术（石家庄）有限公司 FGFR inhibitor and medical application thereof
WO2019111998A1 (en) * 2017-12-08 2019-06-13 京ダイアグノスティクス株式会社 Cancer spheroid production method and method for selecting colon cancer patients
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201105584D0 (en) * 2011-04-01 2011-05-18 Imp Innovations Ltd Cancer methods
UY34484A (en) * 2011-12-15 2013-07-31 Bayer Ip Gmbh BENZOTIENILO-PIRROLOTRIAZINAS DISUSTITUIDAS AND ITS USES
EP2695950A1 (en) * 2012-08-10 2014-02-12 Blackfield AG Markers for responsiveness to an inhibitor of the fibroblast growth factor receptor
JP6900314B2 (en) * 2014-12-24 2021-07-07 ジェネンテック， インコーポレイテッド Treatment, diagnosis, and prognosis of bladder cancer

Also Published As

Publication number Publication date
EA201791236A1 (en) 2018-01-31
JO3730B1 (en) 2021-01-31
TW201628655A (en) 2016-08-16
WO2016091849A2 (en) 2016-06-16
CL2017001487A1 (en) 2018-02-23
IL252187B (en) 2020-07-30
EP3229800A2 (en) 2017-10-18
JP2017538708A (en) 2017-12-28
WO2016091849A3 (en) 2016-07-28
SG11201704090WA (en) 2017-06-29
PH12017501064A1 (en) 2017-12-04
MX2017007656A (en) 2017-10-11
SV2017005459A (en) 2018-07-09
KR20170090431A (en) 2017-08-07
US20180333418A1 (en) 2018-11-22
AU2015359538A1 (en) 2017-06-08
IL252187A0 (en) 2017-07-31
CN106999592A (en) 2017-08-01
CA2970181A1 (en) 2016-06-16

Similar Documents

Publication Publication Date Title
BR112017012287A2 (en) pan-fgfr inhibitors and method of identifying cancer patients eligible for treatment with a pan-fgfr inhibitor
CL2019001874A1 (en) Context-permissive isoform-specific tgfß1 inhibitors and their use.
BR112016017700A2 (en) method for treating a cancer in an individual, drug, kit, method, use or kit, and, method, drug or kit
NI201700035A (en) USE OF FGFR MUTANT GENE PANELS IN THE IDENTIFICATION OF CANCER PATIENTS WHO WILL RESPOND TO TREATMENT WITH AN FGFR INHIBITOR
MX2022008868A (en) Treatment of cancer with tg02.
BR112018067330A2 (en) method for treating patient with tumor burden
BR112017008628A2 (en) combination therapy comprising ox40 binding agonists and tigit inhibitors
EA201890512A1 (en) METHODS OF TREATING PATIENTS WITH MALIGNANT TUMORS WITH THE USE OF PHARNESILTRANSFERASE INHIBITORS
CO7151491A2 (en) Method for identifying the origin of a cancer of unknown primary origin
BR112018008503A2 (en) method for treating small cell lung cancer, method for treating a subject, method for selecting a subject with cancer
EA201691866A1 (en) TUMOR LYMPHOCYTES PERMITTING FOR ADAPTIVE CELL THERAPY
CL2015002807A1 (en) Combination therapy
CY1123290T1 (en) COMPOUNDS AND METHODS OF USE
JOP20190199A1 (en) Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor
BR112018001853A2 (en) methods for treating a disorder and for improving the treatment of a disorder
AR092899A1 (en) USE OF MASITINIB FOR THE TREATMENT OF CANCER IN SUB-POPULATIONS OF IDENTIFIED PATIENTS USING PREDICTION FACTORS
BR112016024332A2 (en) methods for treatment, for determining compounds to be used, for patient selection, for monitoring therapeutic efficacy, for optimizing therapeutic efficacy, for identifying a biomarker, article of manufacture, use of gdc-0941 , gdc-0941 and an endocrine therapy agent and compound for use
MA40364A (en) Combination therapy for treatment of cancer
BR112016016101A2 (en) METHODS FOR DETERMINING THE STATUS OF AN INFLAMMATORY DISORDER, FOR MONITORING THE PROGRESSION OF AN INFLAMMATORY DISEASE, OR MONITORING THE EFFECTIVENESS OF A TREATMENT, KIT, AND USE OF DETERMINING THE PRESENCE OR LEVEL OF TESNACIN-C CITRULINADA AND/OR ONE OR MORE CITRULINATE TESNACIN-C FRAGMENTS AND/OR AUTOANTIBODIES WITH SPECIFICITY THEREOF
BR112018008882A8 (en) method for treating a proliferative disorder and pharmaceutical
BR112019002036A2 (en) methods of treatment of a colorectal cancer subject, colorectal cancer treatment kit in a human subject, and drug combination for colorectal cancer therapy
BR112017013982A2 (en) combination drug
BR112023020182A2 (en) METHODS FOR TREATING CANCER IN A SUBJECT IN NEED OF THE SAME AND FOR INHIBITING RAS IN A CELL
BR112019020414A2 (en) compositions and methods to detect and treat prostate cancer using progastrin-binding molecules
BR112018009528A2 (en) Method for determining the risk of recurrence of a subject's breast cancer, Method for predicting the responsiveness to therapy of a subject's breast cancer, Methods or treatments for a subject who has not been treated for breast cancer or was treated with chemotherapy for 5 years, methods to recommend treatment for a subject who has breast cancer, method for treating a subject who has breast cancer

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements